-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Sustained Release Injectable...
-
Company Profile
NewCheckmate Pharmaceuticals Inc – Company Profile
Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals), a subsidiary of Regeneron Pharmaceuticals Inc, is a biotechnology company that discover and develop novel approaches for cancer immunotherapy. The company’s lead product, CMP-001, is a CpG oligonucleotide (CpG-A) that activates differentiated potent activator TLR9 present in tumor infiltrating plasmacytoid dendritic cells (pDC). Checkmate Pharmaceuticals is investigating CMP-001 in combination with various drugs such as nivolumab and pembrolizumab for treatment of PD-1 refractory melanoma, first-line melanoma and Head and Neck Squamous Cell Carcinoma. The company’s...
Add to Basket -
Product Insights
Net Present Value Model: Vidutolimod
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vidutolimod Drug Details CMP-001 (CYT-003) is...
-
Report Bundle
26% offTrends in Pharma – Report Bundle (4 Reports)
‘The pharmaceutical sector is witnessing a massive revamp. It has been conventionally slow in the adoption of technology and is now undergoing rapid changes due to the development of several technologies as well as innovations. From modern cancer research facilities to gene treatment centers, the novel association between the human mind and technology has become a self-evolving matter. Post-COVID, equipped with cutting-edge technology, the prominent pharma industry tends to invest increasingly in inter-organizational collaborations to boost a favorable environment for...
-
Report Bundle
50% offInnovations in Pharma – Report Bundle (5 Reports)
Innovations in Pharma Bundle Report Overview The healthcare industry constantly demands innovation, improvement, accessibility, and affordability. The ‘Innovations in Pharma’ bundle highlights the emerging drug development technologies in providing quality healthcare services. Accessing the in-depth insight from the Innovations in Pharma bundle can help you: Make informed decisions about investments, partnerships, and product development Understand your competitors’ strengths and weaknesses, identify areas of opportunity, and develop strategies to stay ahead in the market Anticipate market changes and adjust your strategies accordingly...
-
Product Insights
Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hypopharyngeal Cancer pipeline market report provides a comprehensive overview of the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypopharyngeal Cancer and features...
-
Product Insights
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
B-Cell Hodgkin Lymphoma Pipeline market research report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma...
-
Thematic Analysis
Gene Therapy in Oncology – Thematic Research
Gene therapy is the introduction of exogenous, genetic material into cells to treat a disease. Gene therapies provide therapeutic benefits to patients, especially those suffering from monogenic diseases. Cancers are generally not monogenic in origin, so gene therapies are more likely to be used to treat cancer by modifying gene regulation in tumorigenic pathways and expressing genes in cells that cause them to be recognized as foreign, or to elicit an immune response to tumorigenic cells. Sales of products that...
-
Sector Analysis
Melanoma – Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic...
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2026
The head and neck (HNC) cancer market is expected to experience significant growth between 2016 and 2026 within the seven major markets (US, France, Germany, Italy, Spain, UK and Japan). The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market. Up until the approvals of Opdivo...